Christi Wallace, MD
Family Medicine · Roanoke, INNPI 1346535358
Payments from drug & device makers
Across 317 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$945
- Corium, LLC$647
- AstraZeneca$567
- Amgen$353
- Corcept Therapeutics$353
- Novo Nordisk$287
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,425100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $945 |
| Corium, LLC | 55 | $647 |
| AstraZeneca(2 entities) | 29 | $567 |
| Amgen | 18 | $353 |
| Corcept Therapeutics | 8 | $353 |
| Novo Nordisk | 16 | $287 |
| Lilly USA, LLC | 10 | $275 |
| GSK | 14 | $267 |
| Pfizer | 16 | $259 |
| Adlon Therapeutics L.p. | 12 | $194 |
| Exact Sciences | 11 | $192 |
| Sanofi-aventis U.S. LLC | 9 | $144 |
| Axsome Therapeutics, Inc. | 4 | $92 |
| Sumitomo Pharma America, Inc. | 5 | $90 |
| Tris Pharma Inc | 4 | $86 |
| Merck | 5 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $62 |
| Antares Pharma, Inc. | 3 | $58 |
| Astellas Pharma US Inc | 2 | $55 |
| Boehringer Ingelheim | 3 | $49 |
| Bausch Health US, LLC | 3 | $40 |
| Johnson & Johnson | 3 | $38 |
| Abbott | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Viiv Healthcare Company | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$226
- ZEPBOUND$116
- TRELEGY ELLIPTA$104
- Prolia$103
How this compares
$5,425 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 138 | $177,472 |
| OzempicSemaglutide | 82 | $119,713 |
| FarxigaDapagliflozin Propanediol | 67 | $91,799 |
| JanuviaSitagliptin Phosphate | 35 | $49,412 |
| JardianceEmpagliflozin | 29 | $46,578 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $46,012 |
| EliquisApixaban | 31 | $39,420 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $31,862 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $31,423 |
| XareltoRivaroxaban | 18 | $27,607 |
| AuvelityDextromethorphan Hbr/Bupropion | 22 | $26,694 |
| TrintellixVortioxetine Hydrobromide | 20 | $26,131 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $24,567 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $19,002 |
| ProliaDenosumab | 11 | $18,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $275 | $177,472138 claims |
| Novo NordiskOzempic | $287 | $119,71382 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $567 | $116,36692 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $267 | $66,65375 claims |
| MerckJanuvia, Janumet Xr | $71 | $64,08346 claims |
| Boehringer IngelheimJardiance | $49 | $46,57829 claims |
| PfizerEliquis | $259 | $39,42031 claims |
| AbbVieLinzess, Ubrelvy, Synthroid | $945 | $36,61658 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $144 | $31,42324 claims |
| Johnson & JohnsonXarelto | $38 | $27,60718 claims |
| Axsome Therapeutics, Inc.Auvelity | $92 | $26,69422 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $62 | $26,13120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Roanoke
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.